Tags : Portfolio

BMS to Acquire Forbius for its AVID200 to Expand its

Shots: Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected to be closed in Q4’20 Prior to closing, Forbius’ non-TGF-beta assets will be transferred to a newly formed private company, which will be retained by Forbius’ existing shareholders AVID200 is […]Read More

Bayer to Acquire KaNDy Therapeutics for Augmenting its Women’s Healthcare

Shots: KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020 The acquisition will add KaNDy’s menopause drug to Bayer’s portfolio. KaNDy has published results of its NT-814 in P-IIb study that demonstrated positive results in mod. to sev. vasomotor symptoms due […]Read More

Olympus to Acquire Arc Medical Design for Expanding its Product

Shots: The acquisition will expand Olympus’ offerings in GI therapeutic devices and the development of advanced colonoscopy tools with the aim of improving early detection and treatment of CRC Olympus will obtain full rights to Arc Medical Design’s medical products and will convert its current exclusive distribution rights of Endocuff Vision to a full acquisition […]Read More

Kronos Bio to Acquire Gilead’s SYK Inhibitor Portfolio

Shots: Gilead to receive an up front in cash and convertible notes into Kronos equity, regulatory & commercial milestones along with royalties on sales of products emerges from the acquired programs Kronos to acquire the two clinical-phase assets along with the rest of Gilead’s portfolio of SYK inhibitors. The portfolio includes entospletinib, being evaluated in […]Read More

Novartis Launches Zero Profit Portfolio for Symptomatic Treatment of COVID-19

Shots: Novartis will offer a portfolio of 15 generic and OTC medicines addressing the need of low- and lower-middle-income countries to treat patients with COVID-19 symptoms. The medicines will available governments, NGOs, and other institutional customers in up to 79 countries at zero-profit to support financially strained healthcare systems The Novartis’ COVID-19 portfolio aid to […]Read More

Takeda to Divest a Portfolio of Select OTC and Non-Core

Shots: Takeda will divest a portfolio of ~18 select OTC and prescription pharmaceutical assets including Neosaldina, Nesina, and Dramin sold in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama and Peru to Hypera for a total value ~$825M. The transaction is expected to be close in H2’20 Takeda expects that its ~300 employees supporting the divested assets […]Read More

Takeda to Divest its Portfolio of Select OTC and Non-Core

Shots: Takeda to receive ~$660M for divesting its 20 select prescription pharmaceutical and OTC products traded in Russia, Georgia, and several countries within the Commonwealth of Independent States. STADA to get rights, title, and interest to the products in the portfolio exclusive in these countries. The transaction is expected to close in Q4’19 Additionally, Takeda […]Read More

Jazz Pharmaceutical to Acquire Cavion for the Expansion of its

Shots: Jazz acquires Cavion, in all stock transaction making total deal value $312.5M. Cavion to receive $52.5M up front, ~$260M milestones based on certain clinical, regulatory and commercial activities The acquisition will broaden Jazz’s portfolio of sleep and neurological disorders and with the addition of Cavion’s CX-8998 it will further lead to expansion into movement […]Read More

Biogen To Report New Data of its Biosimilar Anti-TNF Portfolio

Shots: Biogen to present data from BENEFIT study results assessing etanercept in 533 patients with rheumatoid arthritis and axial spondyloarthritis. Additionally, it presents data from pooled analyses of etanercept, infliximab and imraldi in 1,461 patients showing similarity with its reference product @6mos. & @1yr. treatment Biogen’s three biosimilar, Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab) […]Read More